Recipient Title President and General Manager, Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 ChinaFEI 3024038751Issued May 1, 2026Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3024038751.
Violations1
Issue DateMay 1, 2026
Product TypeDrugs
StatusOpen
Letter Details
Firm
Harbin Jixianglong Biotech Co., Ltd.
Location
Recipient Title President and General Manager, Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China
FEI Number
3024038751
Country
China
Issue Date
May 01, 2026
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Subject
CGMP/API/Adulterated and Misbranded Drugs
Harbin Jixianglong Biotech Co., Ltd. FDA Warning Letter, May 1, 2026
Talk to a Specialist